ReviewAdvances in cancer research2024
Deep learning-based multimodal spatial transcriptomics analysis for cancer.
Review in Advances in cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Spatial transcriptomics and artificial intelligence: a scoping review of emerging applications in head and neck pathology.Head and neck pathology · 2026Article
- Advances in Spatial Transcriptomics in Bone.Current osteoporosis reports · 2026Review
- Artificial intelligence and machine learning-driven advancements in gastrointestinal cancer: Paving the way for precision medicine.World journal of gastroenterology · 2026Review
- A spatiotemporal state-inference framework for adaptive immunotherapy in glioblastoma.Frontiers in oncology · 2026Review
- Spatial AI in cancer: mapping immune evasion topology through multi-modal omics and deep learning.Frontiers in oncology · 2026Review
- Digital pathology and artificial intelligence in breast and gynecologic oncology: from molecular prediction to multimodal integration.Frontiers in oncology · 2026Review
- Multifunctional nanoplatforms for optic nerve regeneration integrating anti-inflammatory, epigenetic, and ionic mechanisms with emerging artificial intelligence technologies.Cell biology and toxicology · 2025Review
- AI-Driven Innovations in Neuroradiology and Neurosurgery: Scoping Review of Current Evidence and Future Directions.Cancers · 2025Review
- Deep learning-driven multi-omics analysis: enhancing cancer diagnostics and therapeutics.Briefings in bioinformatics · 2025Review
- Spatial Transcriptomics in Lung Cancer and Pulmonary Diseases: A Comprehensive Review.Cancers · 2025Review
- Artificial Intelligence Advancements in Oncology: A Review of Current Trends and Future Directions.Biomedicines · 2025Review
- Role of metabolic transformation in cancer immunotherapy resistance: molecular mechanisms and therapeutic implications.Discover oncology · 2025Review
- Microbiome in cancer metastasis: biological insights and emerging spatial omics methods.Frontiers in cellular and infection microbiology · 2025Review
- Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The advent of deep learning (DL) and multimodal spatial transcriptomics (ST) has revolutionized cancer research, offering unprecedented insights into tumor biology. This book chapter explores the integration of DL with ST to advance cancer diagnostics, treatment planning, and precision medicine. DL, a subset of artificial intelligence, employs neural networks to model complex patterns in vast datasets, significantly enhancing diagnostic and treatment applications. In oncology, convolutional neural networks excel in image classification, segmentation, and tumor volume analysis, essential for identifying tumors and optimizing radiotherapy. The chapter also delves into multimodal data analysis, which integrates genomic, proteomic, imaging, and clinical data to offer a holistic understanding of cancer biology. Leveraging diverse data sources, researchers can uncover intricate details of tumor heterogeneity, microenvironment interactions, and treatment responses. Examples include integrating MRI data with genomic profiles for accurate glioma grading and combining proteomic and clinical data to uncover drug resistance mechanisms. DL's integration with multimodal data enables comprehensive and actionable insights for cancer diagnosis and treatment. The synergy between DL models and multimodal data analysis enhances diagnostic accuracy, personalized treatment planning, and prognostic modeling. Notable applications include ST, which maps gene expression patterns within tissue contexts, providing critical insights into tumor heterogeneity and potential therapeutic targets. In summary, the integration of DL and multimodal ST represents a paradigm shift towards more precise and personalized oncology. This chapter elucidates the methodologies and applications of these advanced technologies, highlighting their transformative potential in cancer research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.